Church & Dwight
CHD
$93.74
-1.98%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global producer of Arm & Hammer baking soda and a portfolio of brands spanning laundry care, cat litter, oral care, and vitamins. The company has established a distinct competitive identity as a value-focused, brand-building operator, leveraging its iconic Arm & Hammer platform to drive innovation and cross-category expansion while maintaining a dominant share in its core markets. The current investor narrative centers on the company's ability to navigate a challenging consumer environment, with recent financial trends showing modest revenue growth but significant margin pressure, prompting debate over its capacity to deliver consistent earnings growth and defend its market share against intense competition and private label incursion.…
CHD
Church & Dwight
$93.74
Investment Opinion: Should I buy CHD Today?
Rating: Hold. The core thesis is that CHD is a financially stable company with strong brands facing near-term profitability headwinds, making its current valuation fair but not compelling enough for a Buy rating without clearer signs of a fundamental turnaround.
Supporting evidence includes a solid balance sheet (Debt/Equity: 0.55), robust free cash flow generation ($1.093B TTM), and a defensive low-beta profile (0.47). However, these strengths are counterbalanced by concerning fundamentals: a forward PE of 23.38x appears rich relative to modest Q4 revenue growth of 3.93% and a significant 24.2% YoY decline in Q4 net income. The PEG ratio of 1.02 further suggests the stock is fairly valued given its challenged growth profile.
The thesis would upgrade to a Buy if the forward PE compresses below 20x while revenue growth stabilizes above 4% and gross margins demonstrate sequential improvement. It would downgrade to a Sell if revenue growth turns negative or if net income declines further, pushing the trailing PE above 30x without a growth justification. Relative to its own history (trailing PE down from 34.87x) and its challenged fundamentals, the stock is currently fairly valued to slightly overvalued.
Sign up to view all
CHD 12-Month Price Forecast
The outlook for CHD is one of stabilization rather than acceleration. The company's powerful cash generation and clean balance sheet provide a solid foundation and limit severe downside, supporting the high probability (60%) base case of range-bound trading. However, the path to meaningful upside is blocked by demonstrable margin pressures and unimpressive growth, making the bull case less probable (25%). The stance is neutral because the stock appears fairly valued for its current prospects; a shift to bullish would require concrete evidence of margin recovery in the next two quarterly reports, while a miss on those margins would likely trigger a bearish re-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $121.86 and implied upside of +30.0% versus the current price.
Average Target
$121.86
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$75 - $122
Analyst target range
Analyst coverage appears limited based on the provided data, with only one analyst providing estimates for EPS and revenue, which suggests insufficient broad analyst coverage to form a reliable consensus. The single analyst estimates an average EPS of $4.78 and average revenue of $7.22 billion, but without a consensus price target or recommendation distribution, it is impossible to gauge overall sentiment or implied upside. The implications of limited coverage are significant; it often correlates with a stock being a mid-cap name with lower institutional ownership, which can lead to higher volatility and less efficient price discovery, requiring investors to conduct more independent fundamental research rather than relying on Wall Street consensus.
Bulls vs Bears: CHD Investment Factors
The evidence currently tilts bearish, as fundamental pressures on profitability and growth outweigh the company's defensive financial strengths. The most significant bull points are its strong cash flow and solid balance sheet, which provide a margin of safety. However, the severe margin compression and weak revenue trajectory challenge the sustainability of its current valuation premium. The single most important tension in the investment debate is whether CHD's iconic brand portfolio and value positioning can successfully defend margins and reignite consistent earnings growth against intense competition and private label pressure, or if the recent profitability decline marks a longer-term structural challenge.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $1.093 billion. This provides significant financial flexibility to fund dividends, share buybacks, and strategic acquisitions without straining the balance sheet.
- Solid Balance Sheet with Moderate Leverage: A debt-to-equity ratio of 0.55 indicates a conservatively leveraged capital structure. Combined with a current ratio of 1.07, the company has adequate liquidity to navigate economic cycles.
- Defensive Low-Beta Profile: With a beta of 0.47, CHD is significantly less volatile than the broader market. This defensive characteristic is attractive in uncertain economic environments, as evidenced by its smaller maximum drawdown of -18.1% compared to the market's swings.
- Valuation Multiple Contraction: The trailing PE has compressed from 34.87x at the end of Q4 2025 to 27.62x currently, and the forward PE is 23.38x. This suggests the stock is no longer pricing in peak optimism, potentially offering a more reasonable entry point if fundamentals stabilize.
Bearish
- Severe Profitability and Margin Pressure: Q4 2025 net income of $143.5M declined 24.2% year-over-year from $189.2M. Gross margin also compressed sequentially from 45.05% in Q3 to 45.85% in Q4, highlighting persistent inflationary cost pressures and weak pricing power.
- Weak and Volatile Revenue Growth: Q4 revenue growth of 3.93% YoY is modest, and quarterly revenue has been volatile, fluctuating between $1.467B and $1.644B over the past four quarters. This indicates underlying challenges in achieving consistent top-line expansion in a competitive market.
- Elevated Valuation Despite Challenges: A forward PE of 23.38x is elevated for a consumer staples company facing margin compression and modest growth. The PEG ratio of 1.02 suggests the stock is fairly valued to slightly overvalued relative to its growth prospects.
- Poor Relative Performance and Downtrend: The stock is down 27.11% over the past year and underperformed the S&P 500 by 25.26 percentage points. It remains in a downtrend, trading 17.5% above its 52-week low, indicating sustained selling pressure.
CHD Technical Analysis
The stock is in a pronounced downtrend, having declined 27.11% over the past year, and is currently trading near the lower end of its 52-week range, with the latest close of $95.63 sitting just 17.5% above the 52-week low of $81.33. This positioning near multi-month lows suggests the stock is in a value-seeking zone but remains vulnerable to further downside if fundamental concerns persist. Recent momentum shows a stark divergence, with the stock down 12.53% over the past month but up 99.27% over the past three months; this 3-month surge appears to be a recovery from even deeper lows earlier in the year, but the sharp 1-month sell-off indicates that recovery has stalled and selling pressure has re-emerged. Key technical support is clearly defined at the 52-week low of $81.33, while resistance sits at the 52-week high of $106.04; a breakdown below $81.33 would signal a new leg down, whereas a sustained move above the recent recovery highs near $105 would suggest a more durable reversal. The stock's beta of 0.47 indicates it is significantly less volatile than the broader market, which, combined with a maximum drawdown of -18.1%, suggests it has exhibited defensive characteristics even during its decline.
Beta
0.47
0.47x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
-2.8%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | -0.2% |
| 3m | -0.1% | +14.0% |
| 6m | +9.7% | +7.8% |
| 1y | -2.8% | +25.3% |
| ytd | +13.4% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.644 billion representing a 3.93% year-over-year increase; however, examining the quarterly trend reveals volatility, as revenue declined sequentially from Q3's $1.586 billion and has fluctuated between $1.467 billion and $1.644 billion over the past four quarters, indicating underlying challenges in achieving consistent top-line expansion. Profitability remains intact but under pressure, with Q4 net income of $143.5 million and a gross margin of 45.85%, yet both metrics have compressed from the year-ago period's Q4 net income of $189.2 million and gross margin of 44.75%, highlighting inflationary cost pressures and potentially weaker pricing power. The balance sheet and cash flow position is solid, with a debt-to-equity ratio of 0.55 indicating moderate leverage, a current ratio of 1.07 showing adequate short-term liquidity, and robust trailing twelve-month free cash flow of $1.093 billion, which provides ample capacity for dividends, share buybacks, and strategic acquisitions to fuel growth.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE stands at 27.62x, while the forward PE is notably lower at 23.38x, indicating the market expects earnings growth to resume and improve profitability from recent levels. Compared to sector averages, the stock's valuation presents a mixed picture; its forward PE of 23.38x is elevated relative to many consumer staples peers, but this premium may be partially justified by its strong brand portfolio and cash flow generation, though the recent margin compression challenges the sustainability of such a premium. Historically, the current trailing PE of 27.62x is below the stock's own historical highs seen in recent quarters, such as the 34.87x recorded at the end of Q4 2025, suggesting some multiple contraction has already occurred and the stock is no longer pricing in peak optimism, potentially offering a more reasonable entry point if fundamentals stabilize.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is significant margin pressure, with Q4 net income down 24.2% year-over-year and gross margin showing volatility. While revenue grew 3.93% YoY in Q4, the sequential decline from Q3 and quarterly fluctuations indicate an inability to drive consistent top-line expansion, which is critical to justifying its forward PE of 23.38x. The company's heavy reliance on the US market (approximately 80% of sales) creates concentration risk, making it vulnerable to domestic economic softness and competitive dynamics in the consumer staples sector.
Market & Competitive Risks: The stock's elevated forward PE of 23.38x presents valuation compression risk, especially if earnings growth fails to materialize. Intense competition from larger rivals and private label brands threatens market share and pricing power, a concern highlighted by the recent margin trends. The stock's low beta of 0.47 offers defensive characteristics but also means it may not participate fully in market rallies, as evidenced by its severe 1-year underperformance of -25.26% relative to the S&P 500.
Worst-Case Scenario: The worst-case scenario involves a continuation of margin erosion coupled with a revenue decline, triggering multiple compression as the market re-rates CHD from a premium staple to a value trap. This could be catalyzed by a deeper-than-expected consumer pullback or a successful aggressive pricing campaign by competitors. In this adverse scenario, the stock could realistically retest and break below its 52-week low of $81.33, representing a potential downside of approximately -15% from the current price near $95.63. A sustained breakdown could lead to further declines towards the $75-$80 range, aligning with a bear-case PE in the high-teens.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Continued margin compression from inflation and competition, as seen in the 24.2% YoY net income decline. 2) Growth Risk: Inability to accelerate consistent revenue growth beyond the volatile low-single-digits, threatening the premium multiple. 3) Valuation Risk: The forward PE of 23.38x could compress further if earnings disappoint. 4) Market Risk: Despite its low beta, the stock has severely underperformed the market (-25.26% relative strength over 1 year), indicating weak sentiment that could persist.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $95 and $105, assuming muddling growth and stabilized margins. The Bull Case (25% probability) targets $106 to $115, requiring successful margin recovery and accelerated growth. The Bear Case (15% probability) risks a drop to the $81-$90 range if fundamentals deteriorate further. The base case is most likely, anchored by the company's strong cash flow but capped by its growth challenges. The key assumption is that gross margins will find a floor near current levels without significant further erosion.
CHD appears fairly valued to slightly overvalued relative to its near-term fundamentals. The forward PE of 23.38x is elevated for a consumer staples company with challenged profitability. While the multiple has contracted from a trailing high of 34.87x, the PEG ratio of 1.02 suggests the market is paying a fair price for its expected growth. The valuation implies the market expects a stabilization and eventual recovery in earnings, but is not pricing in significant expansion. Compared to its own history, it is cheaper; compared to the growth it is currently delivering, it is not clearly cheap.
CHD is a Hold, not a compelling Buy at current levels. For a risk-averse investor seeking defensive exposure and a stable dividend (yield 1.41%), its strong cash flow and low volatility (beta 0.47) are attractive. However, the significant margin pressure (Q4 net income down 24.2% YoY) and modest growth challenge the valuation, with a forward PE of 23.38x. It would become a good buy for growth-oriented investors only if the price drops further to provide a larger margin of safety (e.g., below $90) or if upcoming earnings reports show clear margin recovery.
CHD is more suitable for a long-term investment horizon of 3+ years. Its low beta (0.47) and dividend make it a poor candidate for short-term trading, as it lacks volatility-driven momentum. A long-term horizon allows investors to benefit from the company's strong brand equity and cash flow generation while waiting for a potential turnaround in profitability. The current transitional period requires patience. Given the need to monitor several quarterly earnings cycles for a trend change, a minimum holding period of 12-18 months is suggested to properly evaluate the investment thesis.